MARINELA contact CAPANU

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study
    Sharon N Teraoka
    Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908 0717, USA
    Breast Cancer Res 13:R114. 2011
  2. ncbi request reprint Misspecification tests for binomial and beta-binomial models
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 27:2536-54. 2008
  3. pmc The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, 307 E 63rd Street, New York, NY 10021, U S A
    Stat Med 27:1973-92. 2008
  4. pmc Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 67:371-80. 2011
  5. pmc Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:3465-71. 2009
  6. doi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
  7. pmc Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
    J Clin Oncol 29:868-74. 2011
  8. pmc Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
    J Clin Oncol 29:884-9. 2011
  9. pmc A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    David H Ilson
    Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 117:1409-14. 2011
  10. ncbi request reprint Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006

Research Grants

  1. Estimating Cancer Risks of Rare Genetic Variants
    Marinela Capanu; Fiscal Year: 2009
  2. Estimating Cancer Risks of Rare Genetic Variants
    MARINELA contact CAPANU; Fiscal Year: 2010

Detail Information

Publications20

  1. pmc Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study
    Sharon N Teraoka
    Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908 0717, USA
    Breast Cancer Res 13:R114. 2011
    ..A subset of these SNPs, selected upon their main effects on contralateral breast cancer risk was further evaluated for interaction with treatment modalities and estrogen receptor (ER) status...
  2. ncbi request reprint Misspecification tests for binomial and beta-binomial models
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 27:2536-54. 2008
    ..Our findings suggest that IOS is strongly competitive, not only against the IM test but also against tests designed for specific binomial and beta-binomial models...
  3. pmc The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, 307 E 63rd Street, New York, NY 10021, U S A
    Stat Med 27:1973-92. 2008
    ..However, further research is needed to validate the application of asymptotic methods to such sparse data...
  4. pmc Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method
    Marinela Capanu
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biometrics 67:371-80. 2011
    ....
  5. pmc Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:3465-71. 2009
    ..Future randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to assess the additional value of HAI therapy in converting patients with hepatic metastases to resectability...
  6. doi request reprint Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial
    Ghassan K Abou-Alfa
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    JAMA 304:2154-60. 2010
    ..The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial...
  7. pmc Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
    J Clin Oncol 29:868-74. 2011
    ..To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with advanced gastroesophageal malignancies...
  8. pmc Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
    J Clin Oncol 29:884-9. 2011
    ..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)...
  9. pmc A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    David H Ilson
    Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 117:1409-14. 2011
    ..Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer...
  10. ncbi request reprint Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006
    ..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma...
  11. doi request reprint Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases
    David J Gallagher
    Department of Medicine, Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA
    Ann Surg Oncol 16:1844-51. 2009
    ..We investigated the relation between response to neoadjuvant chemotherapy and overall survival (OS) in patients with colorectal liver metastases (CLM)...
  12. pmc Variation of breast cancer risk among BRCA1/2 carriers
    Colin B Begg
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    JAMA 299:194-201. 2008
    ..The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers...
  13. doi request reprint Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
    Geoffrey Y Ku
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 62:875-80. 2008
    ..We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer...
  14. pmc Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study
    Jonine L Bernstein
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St Fl 3, New York, NY 10065, USA
    J Natl Cancer Inst 102:475-83. 2010
    ..We investigated whether genetic variants in ATM play a clinically significant role in radiation-induced contralateral breast cancer in women...
  15. pmc Advanced hepatocellular carcinoma: which staging systems best predict prognosis?
    Fidel David Huitzil-Melendez
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:2889-95. 2010
    ..Many staging systems that include both aspects have been developed. It remains unknown, however, which of these systems is optimal for predicting patient survival...
  16. doi request reprint Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer
    Derek G Power
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Weil Cornell Medical College of Cornell University, New York, NY, USA
    J Am Coll Surg 208:173-8. 2009
    ..Laparoscopy is a recommended staging evaluation to identify occult peritoneal metastatic disease. We determined if endoscopic ultrasound (EUS) could improve the selection of patients for laparoscopy...
  17. ncbi request reprint Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study
    Lisbeth Bertelsen
    Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
    J Natl Cancer Inst 100:32-40. 2008
    ..However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status...
  18. doi request reprint Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group
    Jane C Figueiredo
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Clin Oncol 26:1411-8. 2008
    ..To investigate whether oral contraceptive (OC) use and postmenopausal hormones (PMH) are associated with an increased risk of developing asynchronous bilateral breast cancer among women diagnosed with breast cancer younger than 55 years...
  19. pmc Variants in the ATM gene associated with a reduced risk of contralateral breast cancer
    Patrick Concannon
    Department of Biochemistry and Molecular Genetics and Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia 22908 0733, USA
    Cancer Res 68:6486-91. 2008
    ..1-0.6; c.6348-54T>C RR, 0.2; 95% CI, 0.1-0.8]. These data suggest that some alleles of ATM may exert an antineoplastic effect, perhaps by altering the activity of ATM as an initiator of DNA damage responses or a regulator of p53...
  20. ncbi request reprint Reproductive history and risk of second primary breast cancer: the WECARE study
    Joan A Largent
    Epidemiology Division, Department of Medicine, University of California, Irvine, Irvine, CA 92697 7555, USA
    Cancer Epidemiol Biomarkers Prev 16:906-11. 2007
    ..Women with an initial breast cancer diagnosis are at elevated risk of developing subsequent cancer in the contralateral breast. Studies of reproductive factors and contralateral breast cancer (CBC) have provided inconsistent results...

Research Grants3

  1. Estimating Cancer Risks of Rare Genetic Variants
    Marinela Capanu; Fiscal Year: 2009
    ..The research will involve hierarchical statistical modeling, a technique that aggregates the evidence about lots of rare mutations to increase the ability to predict the effects of each mutation individually. ..
  2. Estimating Cancer Risks of Rare Genetic Variants
    MARINELA contact CAPANU; Fiscal Year: 2010
    ..The research will involve hierarchical statistical modeling, a technique that aggregates the evidence about lots of rare mutations to increase the ability to predict the effects of each mutation individually. ..